Patheon appoints new executive vice president

Michael Lytton takes a role that includes corporate development and strategy, and general counsel

Patheon has appointed Michael E Lytton as executive vice president, corporate development and strategy and general counsel.

Lytton was most recently with Biogen Idec, where he was executive vp, corporate and business development reporting to Jim Mullen, previously chief excutive of Biogen Idec and now Patheon's chief executive.

Lytton's 28-year career includes experience in the pharmaceutical and biotech industry. Prior to joining Biogen Idec, he was a general partner with Oxford Bioscience Partners, a venture capital firm investing in therapeutic, diagnostic, and life science tool companies. Prior to this, Lytton practised law for 17 years and specialised in representing biomedical companies.

Lytton is currently chairman of Santhera Pharmaceuticals.

You may also like

Manufacturing

Financial gains for choosing a single-source outsourcing partner

Tufts Center for Drug Development study shows that there are multimillion-dollar benefits of using single-source pharma drug development and manufacturing model
Design & Build

Patheon to invest $45m to support continued growth

Investments by the pharmaceutical solutions provider include facility and equipment expansions in key service areas to meet growing customer demand
Manufacturing

Anticipating the formulation challenges of complex molecules

Patheon's webinar which took place on 28 June, is now available on demand
Manufacturing

Thermo Fisher Scientific to acquire leading CDMO, Patheon

The transaction represents a purchase price of approximately $7.2bn
Manufacturing

Patheon completes sterile expansion at Greenville site

Company invests $26m in sterile Pharmaceutical Development Services suite
You need to be a subscriber to read this article.
Click here to find out more.
Manufacturing

Technology transfers: reaping rewards, reducing risks

There are a number of strategic advantages that companies can achieve in pharmaceutical production by transferring production between sites
Manufacturing

Patheon named Supply Chain Resiliency Partner of the Year

Patheon N.V., a leading global provider of high-quality drug development and delivery solutions to the pharmaceutical and biopharma sectors, has won the “Supply Chain Resiliency Partner of the Year” award by the Global Supply Chain Resiliency Council
Subscribe now